<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Lipid-regulating Drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i590.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i590.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i590.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1032.htm" title="Previous: Levamisole">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i970.htm" title="Next: Ezetimibe">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i590">Lipid-regulating Drugs</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Lipid-regulating Drugs</b>
          has no specific interaction information.
        </p><p><b>Ezetimibe</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of both drugs may increase when  ezetimibe given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td> ezetimibe possibly enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i594.htm">Fibrates</a></td><td>increased risk of cholelithiasis and gallbladder disease when  ezetimibe given with fibrates—discontinue if suspected</td><td></td></tr></tbody></table><p><b>Bile Acid Sequestrants </b> belongs to
      <b>Lipid-regulating Drugs</b>
          but has no specific interaction information.
        </p><p><b>Colesevelam</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><div>Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption </div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> colesevelam reduces absorption of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td> colesevelam reduces absorption of ethinylestradiol </td><td></td></tr><tr><td><a href="41001i270.htm">Glibenclamide</a></td><td> colesevelam reduces absorption of glibenclamide </td><td></td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> colesevelam reduces absorption of levothyroxine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> colesevelam possibly reduces absorption of phenytoin </td><td></td></tr></tbody></table><p><b>Colestipol</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><div>Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption </div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i810.htm">Bile Acids</a></td><td> colestipol possibly reduces absorption of bile acids </td><td></td></tr><tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td> colestipol possibly reduces absorption of cardiac glycosides </td><td></td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td> colestipol reduces absorption of thiazides and related diuretics (give at least 2 hours apart)</td><td></td></tr><tr><td><a href="41001i216.htm">Tetracycline</a></td><td> colestipol possibly reduces absorption of tetracycline </td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td> colestipol reduces absorption of thyroid hormones </td><td></td></tr></tbody></table><p><b>Colestyramine</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><div>Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i1.htm">Acarbose</a></td><td> colestyramine possibly enhances hypoglycaemic effect of acarbose </td><td></td></tr><tr><td><a href="41001i810.htm">Bile Acids</a></td><td> colestyramine possibly reduces absorption of bile acids </td><td></td></tr><tr><td><a href="41001i478.htm">Cardiac Glycosides</a></td><td> colestyramine possibly reduces absorption of cardiac glycosides </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> colestyramine may enhance or reduce anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i525.htm">Diuretics, Thiazide and related</a></td><td> colestyramine reduces absorption of thiazides and related diuretics (give at least 2 hours apart)</td><td></td></tr><tr><td><a href="41001i891.htm">Leflunomide</a></td><td> colestyramine significantly decreases effect of leflunomide (enhanced elimination)—avoid unless drug elimination desired</td><td>Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</td></tr><tr><td><a href="41001i74.htm">Meloxicam</a></td><td> colestyramine increases the excretion of meloxicam </td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td> colestyramine reduces absorption of mycophenolate </td><td></td></tr><tr><td><a href="41001i59.htm">Paracetamol</a></td><td> colestyramine reduces absorption of paracetamol </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> colestyramine may enhance or reduce anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i864.htm">Raloxifene</a></td><td> colestyramine reduces absorption of raloxifene (manufacturer of raloxifene advises avoid concomitant administration)</td><td></td></tr><tr><td><a href="41001i216.htm">Tetracycline</a></td><td> colestyramine possibly reduces absorption of tetracycline </td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td> colestyramine reduces absorption of thyroid hormones </td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> colestyramine possibly reduces absorption of valproate </td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td> colestyramine antagonises effects of <i>oral</i> vancomycin </td><td></td></tr></tbody></table><p><b>Fibrates</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b>possible increased risk of myopathy when  fibrates given with colchicine </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> fibrates enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1061.htm">Daptomycin</a></td><td class="cBV"><b>increased risk of myopathy when  fibrates given with daptomycin (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i970.htm">Ezetimibe</a></td><td>increased risk of cholelithiasis and gallbladder disaese when  fibrates given with ezetimibe—discontinue if suspected</td><td></td></tr><tr><td><a href="41001i265.htm">Insulin</a></td><td> fibrates may improve glucose tolerance and have an additive effect with insulin </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> fibrates enhance anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i600.htm">Statins</a></td><td class="cBV"><b>increased risk of myopathy when  fibrates given with statins </b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> fibrates may improve glucose tolerance and have an additive effect with sulfonylureas </td><td></td></tr></tbody></table><p><b>Bezafibrate</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td>increased risk of renal impairment when  bezafibrate given with ciclosporin </td><td></td></tr></tbody></table><p><b>Ciprofibrate</b> belongs to
      <b>Lipid-regulating Drugs</b>
          but has no specific interaction information.
        </p><p><b>Fenofibrate</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td>increased risk of renal impairment when  fenofibrate given with ciclosporin </td><td></td></tr></tbody></table><p><b>Gemfibrozil</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i1046.htm">Bexarotene</a></td><td class="cBV"><b> gemfibrozil increases plasma concentration of bexarotene—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i920.htm">Nateglinide</a></td><td> gemfibrozil possibly enhances hypoglycaemic effect of nateglinide </td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td class="cBV"><b>increased risk of severe hypoglycaemia when  gemfibrozil given with repaglinide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i600.htm">Statins</a></td><td class="cBV"><b>increased risk of myopathy when  gemfibrozil given with statins (preferably avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Statins</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b>possible increased risk of myopathy when  statins given with colchicine </b></td><td></td></tr><tr><td><a href="41001i1061.htm">Daptomycin</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with daptomycin (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i594.htm">Fibrates</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with fibrates </b></td><td></td></tr><tr><td><a href="41001i163.htm">Fusidic Acid</a></td><td class="cBV"><b>risk of myopathy and rhabdomyolysis when  statins given with fusidic acid—avoid concomitant use and for 7 days after last fusidic acid dose</b></td><td></td></tr><tr><td><a href="41001i599.htm">Gemfibrozil</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with gemfibrozil (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i606.htm">Nicotinic Acid</a></td><td class="cBV"><b>increased risk of myopathy when  statins given with nicotinic acid (applies to lipid regulating doses of nicotinic acid)</b></td><td>Interactions apply to lipid-regulating doses of nicotinic acid</td></tr></tbody></table><p><b>Rosuvastatin</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



















<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  rosuvastatin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with atazanavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of myopathy when  rosuvastatin given with ciclosporin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> rosuvastatin possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with darunavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td>plasma concentration of  rosuvastatin possibly increased by dronedarone </td><td></td></tr><tr><td><a href="41001i1177.htm">Eltrombopag</a></td><td class="cBV"><b>plasma concentration of  rosuvastatin increased by eltrombopag (consider reducing dose of rosuvastatin)</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  rosuvastatin reduced by erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td> rosuvastatin increases plasma concentration of ethinylestradiol </td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with fosamprenavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with indinavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with lopinavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with nelfinavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i674.htm">Norgestimate</a></td><td> rosuvastatin increases plasma concentration of active metabolite of norgestimate </td><td></td></tr><tr><td><a href="41001i675.htm">Norgestrel</a></td><td> rosuvastatin increases plasma concentration of norgestrel </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> rosuvastatin possibly enhances anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with ritonavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  rosuvastatin given with saquinavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  rosuvastatin possibly increased by tipranavir—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Atorvastatin</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td>possible increased risk of myopathy when  atorvastatin given with imidazoles </td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td>possible increased risk of myopathy when  atorvastatin given with triazoles </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with atazanavir </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  atorvastatin increased by clarithromycin </b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with darunavir </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> atorvastatin possibly increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>plasma concentration of  atorvastatin increased by diltiazem—possible increased risk of myopathy</td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td>plasma concentration of  atorvastatin possibly increased by dronedarone </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  atorvastatin reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>possible increased risk of myopathy when  atorvastatin given with erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i638.htm">Ethinylestradiol</a></td><td> atorvastatin increases plasma concentration of ethinylestradiol </td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>plasma concentration of  atorvastatin possibly reduced by etravirine </td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  atorvastatin possibly increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with indinavir </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>increased risk of myopathy when  atorvastatin given with itraconazole </b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with lopinavir </td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td> atorvastatin possibly increases plasma concentration of midazolam </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with nelfinavir </td><td></td></tr><tr><td><a href="41001i673.htm">Norethisterone</a></td><td> atorvastatin increases plasma concentration of norethisterone </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>increased risk of myopathy when  atorvastatin given with posaconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  atorvastatin possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with ritonavir </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td>possible increased risk of myopathy when  atorvastatin given with saquinavir </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  atorvastatin advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>increased risk of myopathy when  atorvastatin given with telithromycin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>Plasma concentration of  atorvastatin increased by tipranavir (increased risk of myopathy—reduce dose of atorvastatin)</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td> atorvastatin may transiently reduce anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p><b>Fluvastatin</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> fluvastatin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  fluvastatin increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i270.htm">Glibenclamide</a></td><td> fluvastatin possibly increases plasma concentration of glibenclamide </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>combination of  fluvastatin with phenytoin may increase plasma concentration of either drug (or both)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  fluvastatin accelerated by rifampicin (reduced effect)</td><td></td></tr></tbody></table><p><b>Pravastatin</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i168.htm">Clarithromycin</a></td><td>plasma concentration of  pravastatin increased by clarithromycin </td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td>plasma concentration of  pravastatin possibly increased by darunavir </td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  pravastatin reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  pravastatin increased by erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td>possible increased risk of myopathy when  pravastatin given with telithromycin </td><td></td></tr></tbody></table><p><b>Simvastatin</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





































<tr><td><a href="41001i1124.htm">Alitretinoin</a></td><td>plasma concentration of  simvastatin reduced by alitretinoin </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with amiodarone </b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i470.htm">Amlodipine</a></td><td>possible increased risk of myopathy when  simvastatin given with amlodipine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with atazanavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td>plasma concentration of  simvastatin reduced by bosentan </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  simvastatin reduced by carbamazepine—consider increasing dose of simvastatin</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with clarithromycin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td> simvastatin enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i579.htm">Danazol</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with danazol </b></td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td>plasma concentration of  simvastatin possibly increased by dasatinib </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>plasma concentration of  simvastatin increased by diltiazem—possible increased risk of myopathy</td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with dronedarone </b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  simvastatin reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with erythromycin (avoid concomitant use)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1153.htm">Eslicarbazepine</a></td><td>plasma concentration of  simvastatin reduced by eslicarbazepine—consider increasing dose of simvastatin</td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with fluconazole—avoid concomitant use</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>plasma concentration of  simvastatin increased by grapefruit juice—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td>plasma concentration of  simvastatin increased by imatinib </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with indinavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with itraconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with ketoconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i299.htm">Miconazole</a></td><td class="cBV"><b>possible increased risk of myopathy when  simvastatin given with miconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with nelfinavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with posaconazole (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td>plasma concentration of  simvastatin increased by ranolazine (consider reducing dose of simvastatin)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  simvastatin possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with ritonavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with saquinavir (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  simvastatin reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  simvastatin advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with telithromycin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b>plasma concentration of  simvastatin increased by ticagrelor (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  simvastatin possibly increased by tipranavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>increased risk of myopathy when  simvastatin given with verapamil </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td>possible increased risk of myopathy when  simvastatin given with voriconazole </td><td></td></tr></tbody></table><p><b>Nicotinic Acid</b> belongs to
      <b>Lipid-regulating Drugs</b>
          and has the following interaction information:
        </p><div>Interactions apply to lipid-regulating doses of nicotinic acid</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i600.htm">Statins</a></td><td class="cBV"><b>increased risk of myopathy when  nicotinic acid given with statins (applies to lipid regulating doses of nicotinic acid)</b></td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i970.htm" title="Ezetimibe">Ezetimibe</a></li><li id="_41001i591"><a href="41001i591.htm" title="Bile Acid Sequestrants ">Bile Acid Sequestrants </a></li><li id="_41001i594"><a href="41001i594.htm" title="Fibrates">Fibrates</a></li><li id="_41001i600"><a href="41001i600.htm" title="Statins">Statins</a></li><li><a href="41001i606.htm" title="Nicotinic Acid">Nicotinic Acid</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1032.htm">Previous: Levamisole</a> | <a class="top" href="41001i590.htm#">Top</a> | <a accesskey="]" href="41001i970.htm">Next: Ezetimibe</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>